Azacitidine-associated pleuropericardial effusion in myelodysplastic syndrome: A case report
- 22 June 2018
- journal article
- research article
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
- Vol. 25 (5), 1248-1252
- https://doi.org/10.1177/1078155218784762
Abstract
Azacitidine, a deoxyribonucleic acid hypomethylating agent, is used in the treatment of myelodysplastic syndrome. Common adverse effects of azacitidine include bone marrow suppression, injection site reactions, nausea, vomiting, diarrhea, and fatigue. This report focuses on pleuropericardial effusions, an infrequently reported and potentially reversible adverse effect of azacitidine. In this case report, pleuropericardial effusion manifested as the sole radiographic finding in the evaluation of cough occurring during the eighth cycle of treatment with azacitidine. Symptoms and radiographic abnormalities resolved with corticosteroids and diuretics, and the patient could continue with therapy.Keywords
This publication has 23 references indexed in Scilit:
- 190 AZACITIDINE CAUSING PLEUROPERICARDIAL EFFUSIONS. SHOULD THE TREATMENT BE CONTINUED OR NOT?Leukemia Research, 2015
- Concise Drug Review: Azacitidine and DecitabineThe Oncologist, 2013
- Revised International Prognostic Scoring System for Myelodysplastic SyndromesBlood, 2012
- Epidemiology of Myelodysplastic SyndromesAmerican Journal Of Medicine, 2012
- Incidence of the myelodysplastic syndromes using a novel claims-based algorithm: high number of uncaptured cases by cancer registriesBlood, 2011
- Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III studyThe Lancet Oncology, 2009
- Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabineInternational Journal of Cancer, 2008
- 5-Azacytidine and 5-aza-2′-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapyOncogene, 2002
- Randomized Controlled Trial of Azacitidine in Patients With the Myelodysplastic Syndrome: A Study of the Cancer and Leukemia Group BJournal of Clinical Oncology, 2002
- Epidemiological Features of Myelodysplastic Syndromes: Results From Regional Cancer Surveys and Hospital-Based StatisticsInternational Journal of Hematology, 2001